Kidney Protection in Type 2 Diabetes: Guideline‑Based Strategies and Emerging Role of Tirzepatide

Current Guideline‑Recommended Kidney‑Protective Therapies

SGLT2 inhibitors are recommended as first‑line therapy for all adults with type 2 diabetes and chronic kidney disease (eGFR ≥ 20 mL/min/1.73 m²), reducing the risk of kidney failure by approximately 30–40 % (KDIGO 2022, Grade 1A) [1][2]
ACE inhibitors or ARBs should be titrated to the maximum tolerated dose in patients with albuminuria > 30 mg/g, as this improves renal outcomes (KDIGO 2020) [3][1]
GLP‑1 receptor agonists are advised for additional cardiovascular and renal protection when SGLT2‑inhibitor and metformin therapy are insufficient (KDIGO 2022) 1
Finerenone (a non‑steroidal mineralocorticoid receptor antagonist) is indicated if albuminuria ≥ 30 mg/g persists despite optimal ACE‑I/ARB and SGLT2‑inhibitor therapy (KDIGO 2022) 2

Tirzepatide may be added for patients with type 2 diabetes and CKD who require additional glycemic control beyond that achieved with SGLT2 inhibitors and metformin (KDIGO 2022) 1
When tirzepatide is initiated together with renin‑angiotensin system blockers, serum creatinine and potassium should be re‑checked 2–4 weeks after start (KDIGO 2022) 1
An early, modest decline in eGFR after starting tirzepatide should not trigger drug discontinuation unless serum creatinine rises > 30 % within 4 weeks, reflecting a hemodynamic effect rather than true kidney injury (KDIGO 2022) 1

Tirzepatide is not yet incorporated into major kidney‑disease guidelines (KDIGO 2022) as a standard therapy for diabetic kidney disease, whereas SGLT2 inhibitors hold a Grade 1A recommendation; the current tirzepatide evidence derives mainly from post‑hoc analyses and observational studies rather than dedicated renal outcome trials (KDIGO 2022) [1][2]

The American College of Physicians, as reflected in the Annals of Internal Medicine, recommends ACE inhibitors or ARBs for patients with diabetes, hypertension, and albuminuria >30 mg/g, titrated to the highest approved dose that is tolerated 4
The Mayo Clinic recommends SGLT2 inhibitors and GLP-1 receptor agonists as the cornerstone of DKD management, providing both kidney and cardiovascular protective benefits 5
SGLT2 inhibitors reduce the risk of kidney failure by 30-40% even when added to maximum ACE inhibitor/ARB therapy, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 6

The standard four-pillar approach to DKD management includes SGLT2 inhibitors for all patients with DKD regardless of glucose control, ACE inhibitors or ARBs titrated to maximum tolerated dose, GLP-1 receptor agonists for additional cardiovascular and kidney protection, and finerenone if albuminuria persists after SGLT2 inhibitor initiation 5, 4, 6